Regeneron Casimvy Gene Therapy from Japan
Casimvy is a gene therapy using CRISPR/Cas9 ex vivo to edit CD34+ cells for sickle cell disease, administered as an immunological cell therapy. It is supplied in measured doses for retail sale, fitting tariff item 3002.15.00 as an immunological product.
Duty Rate — Japan → Canada
0%
Import Tips
• Ensure the product has a Health Canada authorization for import
• Declare it as an immunological product in measured doses for retail sale
• Provide the CBSA with the product's composition and intended use to support classification